within Pharmacolibrary.Drugs.ATC.L;

model L01BC02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.5,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Fluorouracil (5-FU) is an antimetabolite chemotherapeutic agent widely used in the treatment of various cancers, including colorectal, breast, gastric, pancreatic, and head and neck cancers. It interferes with DNA synthesis and cell division by inhibiting thymidylate synthase. 5-FU has been used for decades and remains an important drug in oncology, typically administered intravenously.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients receiving intravenous 5-FU.</p><h4>References</h4><ol><li>R B Diasio, B E Harris,Clinical pharmacology of 5-fluorouracil.,Clinical pharmacokinetics,1989<a href='https://pubmed.ncbi.nlm.nih.gov/2656050/'>https://pubmed.ncbi.nlm.nih.gov/2656050/</a></li><li>Olga V Zhukova, Natalya A Dubovskaya, Daria A Zykova, Evgenia V Arkhipova, Olga A Vorobeva, Olga G Zaborskaya, Sergey D Zaitsev, Alexandra O Grigoreva, Aleksandr A Chicharov, Sergey A Ryabov,Specifics of Pharmacokinetics and Biodistribution of 5-Fluorouracil Polymeric Complex.,Molecules (Basel, Switzerland),2023<a href='https://pubmed.ncbi.nlm.nih.gov/38138585/'>https://pubmed.ncbi.nlm.nih.gov/38138585/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01BC02;
